Vantage Health Names Dr. Steven R. Steinhubl, Director of Digital Medicine at Scripps Translational Science Institute, New Ch...
23 September 2014 - 4:21PM
Business Wire
Vantage Health Inc., (OTCQB:VNTH) ("Vantage Health") or (the
"Company") today announced the appointment of Steven R. Steinhubl,
M.D. as chairman of the board. Dr. Steinhubl replaces interim
chairman, Dr. Kevin Buckman who will remain with the company in an
advisory capacity.
Dr. Steinhubl is director of digital medicine at the Scripps
Translational Science Institute, and a practicing cardiologist at
the integrated Scripps Health system, both in San Diego. Dr.
Steinhubl is working to lead the clinical transformation of
healthcare by enabling the evidence driven adoption of mobile
health technologies through the design and management of pragmatic
clinical trials.
Before joining Scripps Health, Dr. Steinhubl, a cardiologist,
clinical researcher and former pharmaceutical company executive,
served as director of cardiovascular wellness and a
clinician-scientist at the Geisinger Health System based in
Danville, PA.
Among his many accolades with over 25 years in medicine, Dr.
Steinhubl served in the U.S. Air Force from 1991-2002 as a staff
internist in Alaska and afterwards as a Lt. Colonel staff
cardiologist, Lackland Air Force Base, Texas. He has led many
funded research projects and trials in the areas of cardiovascular
science. His copious works in medical research and cardiology have
been published over 400 abstracts, peer-reviewed manuscripts and
book chapters.
He held several academic positions, starting as an Assistant
Professor of Medicine from 1998-2008 at Wilford Hall Medical
Center, Lackland Air Force Base, TX, Associate Professor at
University of North Carolina and University of Kentucky, and now a
Professor at Scripps Translational Science Institute.
Dr. Steinhubl attended Purdue University earning a B.S. in
Chemical Engineering; Georgetown University with a M.S. in
Physiology and attended St Louis University School of Medicine
where he graduated Cum Laude in 1988. He continued post doctorate
training in Internal Medicine completing his internship and
residency at David Grant Medical Center in conjunction with
University of California, Davis School of Medicine and Fellowship
training in Cardiology and Interventional Cardiology at the
Cleveland Clinic.
About Vantage Health
Inc.
Vantage Health Inc. - a mobile health technology company - is
developing personalized and point-of-care screening using Apps
based upon chemical sensing residing within a Bluetooth device that
works with any smartphone. With its foundations in advanced
nanotechnology, the company’s first product, the Vantage Health
Sensor, which is in development, is the convergence of
nano-electronics, bio-informatics, and wireless technology to
create the next generation mobile health application. The first
mobile App is expected to be for lung cancer screening with
additional mobile healthcare Apps in the planning stages. The
company has offices in Redwood City, CA and New York. For more
information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include, among other
things statements with respect to our objectives and strategies to
achieve those objectives, as well as statements with respect to our
beliefs, plans, expectations, anticipations, estimates or
intentions. Such forward-looking statements may also include
statements, among other things, concerning the efficacy, safety and
intended utilization of Vantage’s product candidates, the conduct
and results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to
differ materially include, among others, the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Vantage may not obtain approval to market its product candidates,
or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our
current expectations. We caution that all forward-looking
information is inherently uncertain and actual results may differ
materially from the assumptions, estimates or expectations
reflected or contained in the forward-looking information, and that
actual future performance will be affected by a number of factors,
including economic conditions, technological change, regulatory
change and competitive factors, many of which are beyond our
control. Therefore, future events and results may vary
significantly from what we currently foresee.
For a further list and description of the risks and
uncertainties the Company faces, please refer to the Company’s most
recent Annual Report on Form 10-K and other periodic and other
filings Vantage files with the Securities and Exchange Commission
and are available at www.sec.gov. Such forward-looking statements
are current only as of the date they are made, and Vantage assumes
no obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise.
CSIR Group, LLC. for Vantage HealthChristine Petraglia,
212-386-7082
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
Von Okt 2023 bis Okt 2024